Qiagen : Coronavirus headwinds not as bad as feared, underlying growth attractive
> - Coronavirus headwind not as bad as feared - Revenue of products related to COVID (sample technologies, PCR testing solutions, OEM components) is guided to be about flat y-o-y in FY 2021 (c. $ 600m vs $ 618m in FY 2020) following an incremental jump of >$ 450m y-o-y in 2020. First, in our view this new guidance given in July does not take into account the recent surge of new coronavirus cases in the northern hemisphere in particular, nor does it fully ...Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.